News
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.
Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties, and may opt-in to 50/50 development and profit share of KT-485 in the U.S.
Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback